[ALNY] Alnylam Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 41.29 Change: 1.9 (4.82%)
Ext. hours: Change: 0 (0%)

chart ALNY

Refresh chart

Strongest Trends Summary For ALNY

ALNY is in the long-term down -38% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company?s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-4.83 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 154.11% Sales Growth - Q/Q-22.82% P/E-15.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-9.84% ROE-10.71% ROI
Current Ratio13.51 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin-309.32% Net Profit Margin-263.44% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities598.98 M Cash From Investing Activities-341.33 M Cash From Operating Activities-26.25 M Gross Profit
Net Profit-50.78 M Operating Profit-52.22 M Total Assets1.63 B Total Current Assets1.09 B
Total Current Liabilities80.69 M Total Debt Total Liabilities132.28 M Total Revenue18.54 M
Technical Data
High 52 week148.54 Low 52 week65.07 Last close73.34 Last change0.91%
RSI28.58 Average true range5.13 Beta1.23 Volume734.61 K
Simple moving average 20 days-3.14% Simple moving average 50 days-10.23% Simple moving average 200 days-27.17%
Performance Data
Performance Week5.72% Performance Month0.47% Performance Quart-24.29% Performance Half-26.65%
Performance Year-44.58% Performance Year-to-date-42.27% Volatility daily4.85% Volatility weekly10.84%
Volatility monthly22.22% Volatility yearly76.97% Relative Volume208.92% Average Volume940.78 K
New High New Low

News

2019-04-16 19:13:11 | Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

2019-04-16 07:27:00 | Is Alnylam Pharmaceuticals a Buy Now?

2019-04-15 16:49:08 | Alnylam ALNY Reports Phase III ENVISION Data on Givosiran

2019-04-15 07:00:00 | Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

2019-04-12 18:01:00 | Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

2019-04-12 07:23:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-04-11 09:27:01 | 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

2019-04-10 09:20:01 | Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

2019-04-09 10:51:28 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

2019-04-09 09:03:01 | Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

2019-04-08 13:55:03 | Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics

2019-04-08 11:13:56 | Regeneron forays into gene-silencing therapies with Alnylam tie-up

2019-04-08 09:10:55 | Alnylam trades partner Sanofi for Regeneron in $800M deal

2019-04-08 08:50:06 | What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s NASDAQ:ALNY Earnings Trajectory?

2019-04-08 07:00:00 | Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System CNS Diseases

2019-04-08 07:00:00 | Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System CNS Diseases

2019-04-08 01:00:00 | Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration

2019-03-30 11:31:00 | 2 Biotechs With Big Dates in April

2019-03-27 07:00:00 | Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver EASL International Liver Congress™

2019-03-26 08:26:49 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

2019-03-20 07:07:11 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-03-18 18:51:10 | Alnylam's ALNY Impressive Pipeline Drives Share Price

2019-03-12 10:32:18 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK

2019-03-11 07:00:00 | Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings

2019-03-09 09:31:02 | Why Is Alnylam ALNY Up 3.1% Since Last Earnings Report?

2019-03-07 16:00:00 | Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference

2019-03-07 09:00:02 | Alnylam Stock Down Despite Positive Phase III Givosiran Data

2019-03-06 16:10:08 | Could This Biotech Sacrifice A Buy Point On Drug Safety Questions?

2019-03-06 11:06:00 | Side effects of Alnylam's gene-silencing drug raise concerns, shares slip

2019-03-06 09:12:00 | Alnylam Pharmaceuticals stock down 7.5% after announcing results of Phase 3 givosiran trial

2019-03-06 08:20:40 | After trial success, Alnylam plans to seek FDA approval for 2nd drug

2019-03-06 07:00:00 | Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria

2019-03-05 08:06:59 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

2019-03-04 09:19:00 | Can This Biotech Puppy Run With the Big Dogs?

2019-02-28 09:50:02 | Medicines Company MDCO Q4 Loss Widens, Inclisiran in Focus

2019-02-28 07:00:00 | Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program

2019-02-25 06:43:34 | FDA panel says Karyopharm's cancer drug shows 'significant toxicity'

2019-02-14 18:48:14 | Alnylam Pharmaceuticals Inc ALNY Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-14 12:01:56 | Is Moderna a Buy?

2019-02-12 10:04:00 | Alnylam Pharmaceuticals Is Launched and Ready for More

2019-02-12 08:10:00 | Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group — What Drives Growth in Today's Competitive Landscape

2019-02-08 14:32:00 | Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT

2019-02-08 09:17:26 | The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

2019-02-08 08:06:58 | See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

2019-02-08 07:47:12 | Alnylam's ALNY Q4 Earnings and Revenues Beat Estimates

2019-02-07 23:15:21 | Alnylam Pharmaceuticals, Inc. ALNY Q4 2018 Earnings Conference Call Transcript

2019-02-07 18:15:11 | Alnylam Pharmaceuticals ALNY Reports Q4 Loss, Tops Revenue Estimates

2019-02-07 17:23:14 | Alnylam: 4Q Earnings Snapshot

2019-02-07 16:00:00 | Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity